Monthly Archives: April 2017

Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer

AUSTIN, TX, April 2, 2017 – Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice….

Read More